Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison

Abstract

In the absence of head-to-head trials comparing onabotulinumtoxinA to mirabegron, this indirect comparison indicates that onabotulinumtoxinA may be superior to mirabegron in improving symptoms of urinary incontinence, urgency and urinary frequency in patients with idiopathic OAB.